A single-center, prospective, randomised controlled clinical trial (1:1 treatment ratio), designed to investigate the efficacy and safety of autologous SVF in improving the pregnancy outcome of infertile patients with POI.
Women aged ≥20 and ≤39 years who have childbearing requirements.
Cessation of menstruation or oligomenorrhea for at least 4 months
Serum level of basal follicle stimulating hormone (FSH) >25 U/L at least 2 times (during the second to fourth day of the menstrual cycle or during amenorrhea; The interval between the two tests is 4 weeks)
Serum level of Anti-Mullerian hormone (AMH) ≤1.1 ng/ml
Women with autoimmune diseases.
Women with abnormal and uncontrolled thyroid function.
Women with tumors in bilateral adnexa that are not clearly benign or malignant.
Women with a history of malignant tumors, radiation therapy or chemotherapy.
Rui Yang
Lead sponsor
Peking University Third Hospital
Sponsor institution